… Study design and patients This multicentre, open-label, randomised phase II study was
conducted across 29 Japanese … Hepatobiliary and Pancreatic Oncology Group of Japan Clinical …

… advanced pancreatic cancer. In this study, FOLFIRINOX dosages for Japanese patients were
… in FT-β, compared to 10 out of 31 and 11 out of 36 patients in two separate phase II studies …

… In particular, there has been no report of FOLFIRINOX in Japanese patients with locally …
previous Japanese phase II study of FOLFIRINOX for patients with metastatic pancreatic cancer […

… , Hyogo, Japan. All data were … pancreatic carcinoma, (2) histologically proven pancreatic
carcinoma, (3) refractory APC or intolerance to GP therapy, and (4) no previous chemotherapy …

… In conclusion, this phase II study was unable to demonstrate a reduction in the … with
FOLFIRINOX in Japanese MPC. However, some patients benefited from maintaining chemotherapy …

… This study aimed to assess the efficacy and safety of nivolumab in combination with modified
FOLFIRINOX, which is one of the first line chemotherapy for pancreatic cancer. Methods: …

… (PRODIGE 4/ACCORD 11) conducted in France that demonstrated the superiority of FFX
over gemcitabine alone (4) and a single-arm phase II study conducted in Japan that reported a …

… FOLFIRINOX for pancreatic cancer is generally reserved to young … period, gene-panel
tests using next-generation sequencing have been introduced into clinical practice in Japan, …

… of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic
cancer. … and efficacy of modified FOLFIRINOX for advanced pancreatic adenocarcinoma: A UK …

… than 50% of the patients. Following the performance of this … study, a phase II study of
Japanese patients receiving a modified FOLFIRINOX regimen (85 mg/m 2 oxaliplatin, 150 mg/m 2 …